Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
RNA interference (RNAi)
Marketing
Novartis, Sarepta tipped to drive genomic therapy sales boom
GlobalData tipped the market to balloon to almost $90 billion by 2030, driven by gene therapies such as Sarepta’s Elevidys and Novartis’ Zolgensma.
Nick Paul Taylor
May 15, 2025 12:18pm
Sanofi scores FDA nod for Qfitlia for all types of hemophilia
Mar 28, 2025 3:21pm
Alnylam sees Amvuttra as potential standard of care in ATTR-CM
Aug 30, 2024 10:06am
Arrowhead's plozasiran could reach $700M-plus in sales: report
Apr 16, 2024 3:05pm
Alnylam runs new rare disease awareness series on social media
Feb 22, 2023 9:20am
